In the era of several frontline InO trials, our report provides some evidence for INO re-tx for pts w/ CD22+ dz Of note, our pts had specific characteristics: response to INO1, previous tx w/ chemo-based regimens, prior CD19 tx or lack of CD19, & strong CD22 expression pre-INO2.